📊 MAZE Key Takeaways
Is Maze Therapeutics, Inc. (MAZE) a Good Investment?
Maze Therapeutics maintains a fortress balance sheet with $198.8M cash and 0.11x debt-to-equity, providing sufficient runway for operations. However, the company is operationally distressed with operating losses of $26.6M exceeding revenue of $20M, producing a -132.8% operating margin and -$39.1M negative operating cash flow. Investment thesis hinges on unproven ability to monetize commercialization effectively.
Maze Therapeutics has a strong balance sheet with $189.25M of cash, minimal liabilities, and no long-term debt, which provides meaningful near-term financial flexibility for a pre-revenue biotech. However, the company remains fundamentally unprofitable with no revenue, a $131.12M net loss, and more than $112M of negative free cash flow, so the core fundamental case still depends on future pipeline execution rather than operating performance.
Why Buy Maze Therapeutics, Inc. Stock? MAZE Key Strengths
- Exceptional balance sheet strength: $341.7M stockholders equity with only $38.8M long-term debt provides 5+ years operational runway
- Fortress liquidity with $198.8M cash and 17.88x current ratio eliminates near-term solvency risk
- $20M revenue demonstrates successful transition from pre-clinical to commercialization stage
- Conservative capital structure minimizes financial distress risk and dilution concerns
- Strong liquidity with a 15.50x current and quick ratio
- Debt-free capital structure with $354.97M of equity
- Large cash balance relative to liabilities supports ongoing R&D funding
MAZE Stock Risks: Maze Therapeutics, Inc. Investment Risks
- Severe profitability crisis: operating losses ($26.6M) exceed revenue ($20M) by 33%, indicating fundamentally broken unit economics or excessive overhead
- Negative operating cash flow of -$39.1M combined with -121.0% net margin shows operations cannot self-sustain despite commercialization
- Missing gross profit data obscures whether product margins are viable or if SG&A burden is excessive
- Cash depletion at current burn rate (~$39M annually) requires profitability inflection within 5 years
- No evidence of path to operational breakeven or profitability trend improvement in available data
- No revenue base, so growth quality and commercialization traction are unproven
- Heavy operating and free cash flow losses imply limited cash runway without improvement or new capital
- Negative ROE and ROA reflect weak current capital efficiency
Key Metrics to Watch
- Operating cash flow recovery and inflection to positive (critical survival metric)
- Operating expense ratio trend relative to revenue growth (must narrow significantly)
- Gross margin data disclosure (indicates product-level viability)
- Revenue growth acceleration needed to exceed operating expense growth
- Quarterly burn rate trend and updated cash runway estimates
- Quarterly cash burn and remaining cash runway
- Progress toward revenue generation or major collaboration/milestone income
Maze Therapeutics, Inc. (MAZE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.88x current ratio provides a solid financial cushion.
MAZE Profit Margin, ROE & Profitability Analysis
MAZE vs Healthcare Sector: How Maze Therapeutics, Inc. Compares
How Maze Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Maze Therapeutics, Inc. Stock Overvalued? MAZE Valuation Analysis 2026
Based on fundamental analysis, Maze Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Maze Therapeutics, Inc. Balance Sheet: MAZE Debt, Cash & Liquidity
MAZE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Maze Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $1.25 reflects profitable operations.
MAZE Revenue Growth, EPS Growth & YoY Performance
MAZE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.0M | -$24.2M | $-0.45 |
| Q3 2025 | $2.5M | -$24.8M | $-0.66 |
| Q2 2025 | N/A | -$32.5M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Maze Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
MAZE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Maze Therapeutics, Inc. (CIK: 0001842295)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MAZE
What is the AI rating for MAZE?
Maze Therapeutics, Inc. (MAZE) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAZE's key strengths?
Claude: Exceptional balance sheet strength: $341.7M stockholders equity with only $38.8M long-term debt provides 5+ years operational runway. Fortress liquidity with $198.8M cash and 17.88x current ratio eliminates near-term solvency risk. ChatGPT: Strong liquidity with a 15.50x current and quick ratio. Debt-free capital structure with $354.97M of equity.
What are the risks of investing in MAZE?
Claude: Severe profitability crisis: operating losses ($26.6M) exceed revenue ($20M) by 33%, indicating fundamentally broken unit economics or excessive overhead. Negative operating cash flow of -$39.1M combined with -121.0% net margin shows operations cannot self-sustain despite commercialization. ChatGPT: No revenue base, so growth quality and commercialization traction are unproven. Heavy operating and free cash flow losses imply limited cash runway without improvement or new capital.
What is MAZE's revenue and growth?
Maze Therapeutics, Inc. reported revenue of $20.0M.
Does MAZE pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
Where can I find MAZE SEC filings?
Official SEC filings for Maze Therapeutics, Inc. (CIK: 0001842295) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAZE's EPS?
Maze Therapeutics, Inc. has a diluted EPS of $-0.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MAZE a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Maze Therapeutics, Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MAZE stock overvalued or undervalued?
Valuation metrics for MAZE: ROE of -7.1% (sector avg: 15%), net margin of -121.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MAZE stock in 2026?
Our dual AI analysis gives Maze Therapeutics, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAZE's free cash flow?
Maze Therapeutics, Inc.'s operating cash flow is $-39.1M, with capital expenditures of $93.0K. FCF margin is -196.0%.
How does MAZE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -121.0% (avg: 12%), ROE -7.1% (avg: 15%), current ratio 17.88 (avg: 2).